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At a glance commentary: Females develop pulmonary arterial hypertension more 
frequently than males and loss-of-function BMPR-II mutations underlie heritable 
PAH. Our research shows that, in female pulmonary artery smooth muscle cells 
from BMPR-II mutant mice and patients, there is down regulation of microRNA-96 
associated with concomitant up-regulation of the 5-HT1BR, a direct microRNA-96 
target. We show that this contributes to a proliferative phenotype of female human 
2 
 
pulmonary artery smooth muscle cells and that a microRNA-96 mimic prevents the 
development of pulmonary hypertension in a model of pulmonary arterial 
hypertension. These findings suggest that down-regulation of microRNA-96 and 
associated increases in serotonin-induced proliferation may contribute to the 
pathology of pulmonary arterial hypertension, especially in females. 
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Abstract 
Rational: Females are pre-disposed to pulmonary arterial hypertension (PAH); 
evidence suggests that serotonin, mutations in the bone morphogenetic protein 
receptor II (BMPR-II) gene and estrogens influence development of PAH. The 5-
HT1B receptor (5-HT1BR) mediates human pulmonary artery smooth muscle cell 
(hPASMC) proliferation.  
Objectives: We aimed to determine whether selected microRNAs (miRNAs) 
expressed in PASMCs are influenced by sex, BMPR-II mutations and estrogens 
and contribute to PASMC proliferation in PAH. 
Methods: Expression levels of miRNAs targeting genes related to PAH, estrogen 
and serotonin were determined by quantitative RT-PCR in hPASMCs and mouse 
PASMCs harbouring a heterozygous mutation in BMPR-II (BMPR-IIR899X+/- 
PASMCs). MiRNA-96 targets the 5-HT1BR and was selected for further 
investigation. MiRNA target validation was confirmed by luciferase reporter assay. 
Precursor-miRNA-96 was transfected into hPASMCs to examine effects on 
proliferation and 5-HT1BR expression. The effect of a microRNA-96 mimic on the 
development of hypoxic PH in mice was also assessed. 
Measurements and Main Results: MiRNA-96 expression was reduced in female 
BMPR-IIR899X+/- PASMCs and hPASMCs from female PAH patients; this was 
associated with increased 5-HT1BR expression and serotonin mediated proliferation.  
The 5-HT1BR was validated as a target for miRNA-96. Transfection of precursor-
miRNA-96 into hPASMCs reduced 5-HT1BR expression and inhibited serotonin-
induced proliferation. Restoration of miRNA-96 expression in pulmonary arteries in 
vivo via administration of a miRNA-96 mimic reduced the development of hypoxia-
induced PH in the mouse. We conclude that increased 5-HT1BR expression may be 
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a consequence of decreased miRNA-96 expression in female patient PASMCs and 
this may contribute to the development of PAH. 
250 words  
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Introduction 
Mutations within the Bone Morphogenetic Protein Type II Receptor (BMPR-II) gene 
are associated with ~70% heritable PAH (hPAH) cases and ~10-40% idiopathic 
PAH (1). Loss of function of the BMPR-II receptor results in a decrease in BMPR-II 
signalling translating into aberrant proliferation of pulmonary arterial smooth muscle 
cells (PASMCs) (2). Restoration of the BMPR-II signalling pathway represents a 
novel therapeutic strategy (3). We recently demonstrated, in the hypoxic mouse and 
Sugen 5416/hypoxic (Su/Hx) rat models, that the therapeutic effect of anastrozole, 
an inhibitor of estrogen synthesis, was only observed in females and related to 
restoration BMPR-II signalling (4). BMPR-II mutations exhibit a relatively low 
frequency of disease penetrance (20-30%) suggesting that other factors also 
contribute to the development of PAH.  
Epidemiological studies report a greater incidence of PAH in females; the female to 
male ratio ranges from 3-4:1 (5).  Hence, female sex hormones, primarily 
estrogens, may play a causative role in the development of PAH. 17² -estradiol, the 
main circulating estrogen, increases proliferation of human PASMCs (hPASMCs) 
and anomalous synthesis and metabolism of estrogen have been associated with 
the disease (4, 6, 7). Within the promoter region of the BMPR-II gene there is an 
estrogen response element which may play a role in the suppression of the BMPR-
II receptor expression (8). 
 
Evidence suggests that serotonin is involved in the pathogenesis of PAH. 
Endothelial expression of tryptophan hydroxylase-1 (TPH-1), the rate limiting 
enzyme in the synthesis of serotonin, is increased in remodelled pulmonary arteries 
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from idiopathic patients (9). In addition, TPH-1 knockout mice are protected from 
hypoxia induced pulmonary hypertension (PH) (10, 11). We have shown that only 
female mice develop PH via a serotonin-dependent mechanism, for example mice 
over-expressing the serotonin transporter (SERT), mts1 over-expressing mice and 
mice dosed with dexfenfluramine (6, 12, 13). This PH phenotype is estrogen-
dependent and suggests that female sex and estrogen influence the development 
of PH in these serotonin-dependent models. Serotonin is a potent mitogen and 
vasoconstrictor in the pulmonary vasculature acting through the SERT and 5-
hydroxytryptamine1B receptor (5-HT1BR)(14, 15). The expression of TPH1, SERT 
and the 5-HT1BR in hPASMCs is increased by 17β-estradiol (6). 
MicroRNAs (miRNAs) are non-coding RNA sequences that have the ability to direct 
expression of genes in a post-transcriptional manner through either degradation of 
target mRNA or silencing of mRNA translation. Several miRNAs have recently been 
shown to play a role in PAH pathophysiology (16). Literature suggests that sex 
hormones i.e. estrogens have the ability to regulate the expression of miRNAs (17) 
which led us to speculate whether sex can also influence expression of miRNAs. 
Thus, in the present study we investigated whether sex and/or BMPR-II expression 
affects miRNA expression within PASMCs and hence the expression of genes that 
may influence the development of PAH. 
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Methods 
 
Pulmonary Artery Smooth Muscle Cells 
PASMCs derived from knock-in mice harbouring a heterozygous mutation in 
BMPR-II (R899X) and littermate wild type (WT) control mice were prepared as 
described previously (18) and in online supplement. These mice develop 
spontaneous pulmonary hypertension (19). Human PASMCs were prepared as 
described previously and in online supplement (6).  
 
Cell Proliferation Assay 
To assess proliferation, PASMCs were counted using the haemocytometer 
approach as described previously (6). 
 
hPASMCs transfection with miRNA-mimic 
HPASMCs were transfected with either 1nM precursor (pre)-miR-96 (Ambion, 
PM10422) or pre-miRNA-negative control (Ambion, AM17110 #1) as described in 
the online supplement. For expression analysis each condition was performed in 
biological replicates to allow for RNA and protein harvest 48hrs and 72 hrs post-
transfection respectively. For proliferation analysis PASMCs were then quiesced in 
0.2% FBS and the proliferation protocol followed as per online supplement. 
 
Taqman quantitative-PCR Analysis of miRNAs and mRNAs 
Total RNA extraction and Taqman quantitative RT-PCR were conducted as 
previously described (16, 20) and in online supplement.  
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Western Blot Analysis of Protein 
Protein extraction and Western blot analysis was carried out as described 
previously (7, 16) and in online supplement. 
 
Pulmonary arterial remodelling 
Remodelled pulmonary arteries were investigated by elastin-picrosirius red staining 
as previously described (16, 20) and in online supplement. 
 
Luicferase Reporter Assay 
The psi-CHECK-2 dual luciferase reporter vector (Promega) was utilised for the 
reporter assay as described in online supplement. Luciferase activity was measured 
using the Dual-Glo Luciferase Assay System (Promega) and luminescence 
detection performed via LUMIstar OPTIMA microplate reader (BMG Labtech). 
 
Chronic Hypoxia 
Female WT C57/Bl (Charles River) mice aged 2 months old were exposed to 14 
day hypobaric hypoxia (10% O2, 550mbar) as described previously (21). Mice 
maintained in normoxic conditions (21% O2, 1000mbar) were studied as controls.  
 
Administration of miRNA-96 mimic 
To assess whether miRNA-96 was involved in the pathology of pulmonary 
hypertension, the miRNA-96 mimic (Applied Biosystems, #MC10422) was 
administered intravenously via the tail vein once a week for the 2 weeks of hypoxic 
exposure. See online supplement for further details.   
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Anastrozole-treated mice 
Lungs from mice treated with anastrozole 3mg/kg, or vehicle 1% 
carboxymethylcellulose via subcutaneous injection for 14 days (4) were studied to 
examine the influence of endogenous estrogen depletion on miRNA-96 regulation.  
 
In Vivo Assessment of PH 
Measurements of right ventricular systolic pressure (RVSP), right ventricular 
hypertrophy (RVH) and pulmonary vascular remodelling were performed as 
previously described (4, 7) and in the online supplement.  
 
In-situ Hybridisation 
Localisation of miRNA-96 within pulmonary arteries was performed by in-situ 
hybridisation as previously described (22) and in the online supplement. 
 
Analysis of Data 
Values are expressed as mean ± standard error of the mean (SEM). A t-test or 1-
way ANOVA followed by Tukey’s post-hoc test was performed to evaluate the 
statistical significance between all groups where appropriate. A probability level of 
p<0.05 was defined as being statistically significant. 
 
Results 
Proliferation and miRNA expression in BMPR-IIR899X+/- PASMCs 
Female BMPR-IIR899X+/- PASMCs were more proliferative to PDGF and serotonin 
compared to male BMPR-IIR899X+/- PASMCs (Figure 1A). We examined miRNAs that 
are associated with PAH, hypoxia, serotonin and estrogen systems in the female 
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and male BMPR-IIR899X+/- PASMCs. We examined miRNA-503 [targets e.g. 
fibroblast growth factor 2], miRNA-145 [targets krueppel-like factor 5 (23)], miRNA-
155 [targets e.g. hypoxia-inducible factor ±](24). We also studied miRNAs targeting 
ERα (miRNA-22, miRNA-206 (25)), CYP1B1 (miRNA-27b (26)), the 5-HT1BR 
(miRNA-96 (27)) or SERT (miRNA-16 (28)). 
There was no significant difference between the expression of miRNAs 16, 22 and 
27b in male or female BMPR-IIR899X+/- PASMCs vs. WT cells (Figure E1). MiRNA-
145 and miRNA-206 were significantly increased in both female and male BMPR-
IIR899X+/- PASMCs compared to WT. MiRNA-155 was down-regulated in female 
BMPR-IIR899X+/- PASMCs compared to WT and up-regulated in male BMPR-IIR899X+/- 
PASMCs compared to WT. There was reduced expression of miRNA-503 in female 
BMPR-IIR899X+/- PASMCs compared to WT (Figure E1).  
Expression of miRNA-96 was reduced by ~80% in female BMPR-IIR899X+/- PASMCs 
compared with their WT controls; expression was equal in male BMPR-IIR899X+/- 
PASMCs compared with their WT controls (Figure 1B). In WT PASMCs, there was 
no significant difference in miRNA-96 expression between female and male. In the 
BMPR-IIR899X+/- PASMCs there was decreased expression of miRNA-96 in females 
compared to males. In silico analysis (miRwalk http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/) suggested miRNA-96 may target the 5-HT1BR. 
Therefore we analysed the expression of the 5-HT1BR in female and male BMPR-
IIR899X+/- PASMCs.  5-HT1BR expression was only increased in female BMPR-
IIR899X+/- PASMCs (Figure1C and D) and accompanied by a decrease in miRNA-96 
expression.   
Our rationale for focussing our studies on miRNA-96 was that this is the only known 
miRNA to target the 5-HT1BR (27); the 5-HT1BR mediates pathogenic effects of 
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serotonin in PAH(14, 21). In addition, a role for miRNA-96 in PAH has not 
previously been described, hence this novel sex-specific microRNA-96/5-HT1BR 
axis/BMPR-II was worthy of further investigation. 
 
MiRNA-96 expression in hPASMCs 
MiRNA-96 was also down-regulated in PASMCs from female PAH patients 
compared to non-PAH patient controls (Figure 2A). Consistent with findings from 
the BMPR-IIR899X+/- PASMCs, there was no change in male patient PASMCs (Figure 
2A). Notably, 5-HT1BR expression was only increased in female PAH patients 
(Figure 2B and C).  
 
Validation of 5-HT1BR as a direct target of microRNA-96 
To assess transfection conditions in HeLa cells we performed qRT-PCR analysis to 
examine the mature form of miRNA-96 following pre-miR-96 and pre-miRNA-
negative control transfections.  A significant increase in miRNA-96 expression in the 
pre-miRNA-96 transfected cells was observed compared to control with no increase 
observed in the pre-miRNA-negative control group (Figure 3A). Luciferase reporter 
assay confirmed a miRNA-96 binding site in the 3’UTR of 5-HT1BR mRNA as pre-
miRNA-96 was able to significantly reduce luciferase activity at a concentration of 
25nM with pre-miRNA-negative control showing no significant reduction in 
luciferase activity of the 5-HT1BR construct (Figure 3B). Importantly pre-miRNA-96 
had no effect on reducing luciferase activity of the psi-CHECK-2 control vector and 
of the mutated 5-HT1BR construct (Figure 3B).  
 
miRNA-96 and human PASMC proliferation 
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The proliferative response to serotonin after 72 hours was only observed in female 
patient PASMCs and was inhibited by the 5-HT1BR selective antagonist SB224289 
(Figure 4A-D). The selective 5-HT1BR agonist, CP94253, induced proliferation only 
in female patient PASMCs and this was inhibited by SB224289 (Figure 4A-D). 
Direct over-expression of miRNA-96 (Figure 5A) did not affect 5-HT1BR mRNA 
expression (Figure 5B) but did significantly decrease endogenous 5-HT1BR protein 
expression (Figure 5C). Pre-miRNA-96 abolished serotonin-induced proliferation 
(Figure 5D). Moreover, the effect of pre-miRNA-96 was comparable to the effects of 
the 5-HT1BR antagonist SB224289 (Figure 5D). These results suggest that miRNA-
96 expression can regulate 5-HT1BR-mediated proliferation in female patient 
PASMCs. 
 
The influence of estrogen on miRNA-96 
17β-estradiol decreased miRNA-96 expression (Figure 6A) but did not significantly 
affect 5-HT1BR mRNA expression (Figure 6B). To determine if endogenous 17β-
estradiol also influences miRNA-96 expression we assessed miRNA-96 and 5-
HT1BR protein expression in lung from female and male mice that had been dosed 
with an aromatase inhibitor anastrozole. These mice have depleted circulating and 
local lung synthesis of estrogen and elevated BMPR-II signalling (4). MiRNA-96 
was elevated in the lungs from the estrogen-depleted female mice   (Figure 6C) and 
this was accompanied by a decrease in 5-HT1BR mRNA expression (Figure 6D). No 
changes in miRNA-96 and 5-HT1BR mRNA expression were observed within male 
lung tissue (Figure E2). 
 
In vivo effect of a miRNA-96mimic in the hypoxic mouse 
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We determined if a miRNA-96 mimic would prevent the development of hypoxia-
induced PH (associated with decreased BMPR-II signalling (4, 29)) and if any 
therapeutic effect was related to 5-HT1BR expression.  Firstly we confirmed that 
MaxSuppressor™ In Vivo RNA-LANCEr II delivered miRNA-96 mimic to the 
pulmonary arteries and specifically their medial layer. Figure 7A demonstrates that 
miRNA-96 expression was increased in the pulmonary arteries following 
administration of the miRNA-96 mimic. From in situ hybridisation we report that the 
miRNA-96 expression is localised within the smooth muscle medial layer of the 
pulmonary artery (Figure 7B). The miRNA-96 mimic reduced hypoxia-induced 
increases in RVSP (Figure 7C) and RVH (Figure 7D) and inhibited pulmonary 
vascular remodelling (Figure 7E and F). Importantly, the miRNA-96 mimic had no 
effect under normoxic conditions (Figures 7C-F) and did not affect mean systemic 
arterial pressure and heart rate amongst experimental groups (Figure E3). We 
confirmed that the hypoxic mouse demonstrates decreased BMPR-II mRNA 
expression (Figure 8A). MiRNA-96 expression was decreased by hypoxia and 
restored following the administration of the miRNA-96 mimic (Figure 8B). 5-HT1BR 
protein expression was markedly increased in the hypoxic lung and the miRNA-96 
mimic returned 5-HT1BR expression to normoxic levels (Figure 8C). 
  
Discussion 
Sexual dimorphism of miRNA expression has been recognised within both 
physiological and pathological processes (30, 31). However, this is the first study to 
observe sex differences in miRNA expression with regards to PAH. Through in vitro 
cell culture models and in vivo animal studies we present novel data demonstrating 
how miRNA-96, under the potential influence of estrogen, plays a role in the 
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development of PH in a sex-dependent manner, by regulating 5-HT1BR expression 
and hence serotonin-induced proliferation.  
We have previously demonstrated that female mouse lung displays decreased 
BMPR-II and Id1 expression compared to male lung (4). We have also 
demonstrated that, as a consequence of mutation in BMPR-II, there is unopposed 
p38MAPK/ERK signalling and increased proliferation in hPASMCs (2). PDGF 
induced proliferation only in female non-PAH hPASMCs, and we attribute this to 
decreased BMPR-II signalling in these cells (32). These observations are consistent 
with our observation that the female BMPR-IIR899X+/- PASMCs proliferate to a greater 
extent to PDGF and serotonin compared to male BMPR-IIR899X+/- PASMCs. We 
have previously shown that administration of serotonin unmasks a PH phenotype in 
BMPR-II+/- mice (26). This is consistent with our novel observation that there is an 
increase in the proliferative response to serotonin and 5-HT1BR expression in 
female BMPR-IIR899X+/- PASMCs, associated with a decrease in miRNA-96 
expression.  
To examine if these observations translated to human tissue, we demonstrated that 
serotonin-induced proliferation of hPASMCs from female patients was mediated by 
the 5-HT1BR as the effect was replicated by a 5-HT1BR agonist and abolished by a 
5-HT1BR selective antagonist. These results are consistent with previous studies 
showing the importance of the 5-HT1BR mediating hPASMC proliferation (21, 23). 
MiRNA-96 expression was decreased in female PAH patient PASMCs correlating 
with an increase in 5-HT1BR expression. This is consistent with our observations in 
female mouse BMPR-IIR899X+/- PASMCs, where miRNA-96 expression is decreased 
and 5-HT1BR expression is increased compared with male mouse BMPR-II
R899X+/- 
PASMCs where there was no differential effect.  
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Interestingly, proliferation to serotonin in hPASMCs was only observed in female 
patient PASMCs, despite low expression levels of the 5-HT1BR in male patient and 
control PASMCs. The 5-HT1BR is Gi-linked and Gi-linked responses are regulated 
by synergistic influences such that a threshold for activation is required (33, 34).   
Indeed, activity and /or expression of the 5-HT1BR can be increased synergistically 
by Gq-linked receptor stimulation (14, 35-37), estrogen (6), co-activation of the 
serotonin transporter (14, 38, 39) and pERK (40, 41). Estrogen synthesis is 
increased in female hPASMCs (4) providing a stimulus for over-expression of SERT 
and 5-HT1BR (6) and SERT expression is increased in patient PASMCs (42). In 
addition, pERK2 expression is elevated in female hPASMCs and further enhanced 
in PASMCs from PAH patients (2, 41). In addition there is increased expression of 
Gq-linked receptors (e.g. PDGF, endothelin-1(43)) in PASMCs from patients with 
PAH. Hence female hPASMC from PAH patients are influenced by a unique 
combination of synergins (SERT, 5-HT1BR, Gq-stimulation, estrogen) that can 
facilitate 5-HT1BR-mediated responses.  
In silico bioinformatic analysis suggests the 5-HT1BR is a putative target of miRNA-
96. In addition, a polymorphism in the 3’UTR of the 5-HT1BR mRNA disrupts binding 
of miRNA-96 (27). We validated 5-HT1BR was a target of miRNA-96 through 
luciferase reporter assay. Additionally, we demonstrated direct over-expression of 
miRNA-96 (via transfection of pre-miRNA-96) in hPASMCs could decrease 
expression of target 5-HT1BR protein in in vitro cell culture.  This acute over-
expression of the miRNA-96 had no effect on 5-HT1BR mRNA suggesting that after 
48 hours the miRNA-96 is binding to the 3’UTR of 5-HT1BR mRNA, silencing 
translation to protein without actual degradation of the mRNA.  
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We demonstrated direct over-expression of miRNA-96 ablated the ability of 
serotonin to induce proliferation of female PAH patient PASMCs which 
accompanied a decrease in 5-HT1BR expression. Thus within the female PAH 
patient PASMCs, down-regulation of miRNA-96 may lead to over-expression of 5-
HT1BR which subsequently increased the capacity of serotonin to induce 
proliferation. This is the first report that miRNA-96 expression influences distal 
hPASMCs proliferation and that manipulation of miRNA-96 can influence 
proliferation through targeting the 5-HT1BR. It is distal PASMCs that contribute to 
pulmonary vascular remodelling but it is of interest that down-regulation of miRNA-
96 may mediate an increase in BMP-4 signalling in proximal PASMCs which 
demonstrate a distinct phenotype and are less involved in the pathobiology 
associated with PAH. 
Little is currently known about the role miRNA-96 plays in vascular physiology and 
pathology. Aberrant expression of miRNA-96 has been observed in cancer biology 
where it has been describes as being either oncogenic (44) or anti-oncogenic (45) 
and miRNA-96 has previously been associated with breast cancer (46). Breast 
cancer is a disease strongly influenced by estrogen and suggests that there could 
be a link between estrogen and miRNA-96 expression. Indeed estrogen can alter 
miRNA expression through three mechanisms, firstly through estrogen-response-
elements (ERE) in the promoter element of the pri-miRNA gene (47), secondly 
through transcription of estrogen related genes e.g. c-MYC which can in turn 
interact with transcription of primary-miRNA gene (48) and thirdly through 
interaction with miRNA biogenesis as there is an ER± binding site in the promoter 
region of the Dicer gene (17). We have previously demonstrated that estrogen 
increases the protein expression of the 5-HT1BR in hPASMCs (8). It was therefore 
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of interest to investigate if estrogen can influence 5-HT1BR expression through 
modulating epigenetic control. Stimulation of hPASMCs with estrogen decreased 
the expression of miRNA-96 suggesting that estrogen could influence 5-HT1BR 
expression via regulation of miRNA-96. This is consistent with bioinformatic 
analysis showing the primary-miRNA-96 gene harbours an ERE in the promoter 
region (49). It is equally possible that estrogen could influence miRNA-96 
expression indirectly though reduction in BMPR-II signalling (8) as Smads are 
multifunctional proteins that modify gene expression themselves, transcriptionally 
through DNA binding and post-transcriptionally through pri-miRNA binding and 
regulation of miRNA processing. For example, it has been reported that the 
expression of miRNA-21 is influenced by BMP signalling. Here, SMAD proteins 
interact with DROSHA to increase the biogenic processing of pri-miRNA-21 into 
pre-miRNA-21 and finally into mature miRNA-21 (50).  It is also known that pre-
miRNAs may compete with their mature miRNA and hence serve as post-
transcriptional regulators of miRNA activity (51). Regulation of gene activity by 
miRNAs may therefore be affected by changes in BMPR-II/Smad signalling; 
decreased BMPR-II signalling by estrogen may facilitate the gene-silencing effects 
of miRNA-96 indirectly via decreased pre-miRNA processing.  
Previous studies have shown that exogenously administered estrogen can actually 
protect against PH in male mice (52). We recently demonstrated expression of 
aromatase (the estrogen synthesising enzyme) in human, rat and mouse pulmonary 
artery smooth muscle and that the expression of aromatase was greatest in 
females (4). In addition we showed that inhibition of endogenous aromatase by 
anastrozole increases lung BMPR-II expression and can prevent and reverse PH in 
the hypoxic mouse and rat Su/Hx model but only in females (6). Anastrozole 
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depletes all endogenous estrogen, both circulating (4) and vascular. This suggests 
that endogenous estrogen plays a role in the development of PH in female mice 
and rats via restoration of BMPR-II signalling, but not the males and that the 
combination of circulating estrogen and local endogenous synthesis of estrogen in 
pulmonary arteries drives a PH phenotype in females. Lungs from mice treated with 
anastrozole demonstrated a significantly higher expression of miRNA-96 compared 
to control lung. This increase in miRNA-96 was associated with a decrease in 5-
HT1BR expression and was only observed in lungs from female mice not males. 
Collectively, our results suggest that endogenous estrogen regulates BMPR-II and 
miRNA-96 expression only in female lung.  This supports the hypothesis that sex 
plays an important role in the regulation of miRNAs and BMPR-II. Indeed we have 
recently demonstrated that hPASMCs from non-PAH females have reduced BMPR-
II signalling compared with male hPASMCs and this contributes to increased 
proliferative responses in the female hPASMCs (32). As PAH is more frequently 
presented in women and endogenous estrogens may influence this, it also raises 
the question as to whether or not female and male PAH patients may require 
different therapeutics. This concept has previously been addressed with regards to 
current PAH treatments where it was observed that women responded better to 
endothelin-1 receptor antagonists compared to men (53). 
To investigate if restoration of miRNA-96 expression in vivo can protect against PH 
via the 5-HT1BR, we performed an in vivo study to examine the effects of a miRNA-
96mimic. BMPR-II expression is reduced in the hypoxic mouse, the monocrotaline 
rat and the Sugen/hypoxic rat (4, 54, 55). Here we utilised the hypoxic mouse 
model of PH which produces a robust disease phenotype including decreased 
BMPR-II signalling. We confirmed that BMPR-II mRNA expression was reduced in 
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the lungs of the hypoxic mice. We report that 5-HT1BR protein expression is 
markedly elevated in the lungs from the hypoxic mice whilst miRNA-96 expression 
is reduced. In situ analysis demonstrated that the miRNA-96 expression is primarily 
in the medial smooth muscle cell layer of the pulmonary arteries. We showed i.v. 
administration of the miRNA-96 mimic delivered the miRNA-96 to the pulmonary 
arteries and also that the miRNA-96 mimic reduced hypoxic-induced increases in 
RVSP and RVH and prevented pulmonary vascular remodelling. This was 
associated with an increase in lung miRNA-96 expression and decrease in 5-HT1BR 
expression. This substantiates our hypothesis that PH is associated with increased 
5-HT1BR-mediated remodelling/proliferation under the control of miRNA-96. The 
miRNA-96 mimic had no effect on mean systemic arterial pressure or heart rate 
suggesting that this therapeutic strategy could be pulmonary selective.  
In summary, the present work suggests that estrogen and BMPR-II deficiency can 
decrease miRNA-96 expression in PASMCs causing an increase in 5-HT1BR 
expression and this may influence the pathobiology of PAH in females.  In addition, 
a miRNA-96 mimic can reduce lung 5-HT1BR expression in vivo and can prevent the 
development of experimental PH (see Figure 8D for summary). Further study into 
the potential of a miRNA-96-mimic as a novel therapeutic strategy in PAH is 
warranted. 
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Figure 1.  Characteristics of pulmonary artery smooth muscle cells (PASMCs) in 
female and male BMPR2R899X+/- mice (BMPR-IIR899X+/- PASMCs) and wildtype (WT) 
controls. (A) Proliferative responses after 72 hours to 10% FBS, PDGF and 
serotonin (5-HT) in male and female BMPR-IIR899X+/- PASMCs (n=3, in triplicate). (B) 
Expression of miRNA-96 in male and female BMPR-IIR899X+/- PASMCs and WT 
control cells (n=8, all isolates repeated 3 times). The expression of 5-HT1BR mRNA 
(C) and protein (D) in male and female BMPR-IIR899X+/- PASMCs and WT control 
cells (n=6, all isolates repeated 3 times) and representative immunoblot of 5-HT1BR 
protein expression in male and female BMPR-IIR899X+/- PASMCs and WT control 
cells. Data displayed as mean SEM. *P<0.05, **, ++P<0.01, ***P<0.001 determined 
by one-way analysis of variance with Tukey’s post test. 
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Figure 2. Expression of miRNA-96 and 5-HT1BR in human pulmonary artery smooth 
muscle cells (PASMCs). (A) Expression of miRNA-96 in human PASMCs from 
female and male PAH patients and non-PAH patient control (n=4-6, all isolates 
repeated 3 times). The expression of 5-HT1BR mRNA (B) and protein (C) in human 
PASMCs from female and male PAH patients and non-PAH patient control (n=4-6, 
all isolates repeated 3 times) and representative immunoblot of 5-HT1BR protein 
expression in human PASMCs from female and male patient and non-patient 
control. Data displayed as mean SEM. *P<0.05, determined by one-way analysis of 
variance with Tukey’s post test. 
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Figure 3. Validation of miRNA-96 gene target 5-HT1BR. (A) The effect of pre-
miRNA-96 transfection on the expression of miRNA-96 (n=3). (B) The effect of pre-
miRNA-96 on the luciferase activity of the psi-check-2 control construct, the 5-
HT1BR construct and mutated 5-HT1BR construct (n=3, all isolates repeated 3 
times). Data displayed as mean SEM. **P<0.01, ****P<0.001 determined by one-
way analysis of variance with Tukey’s post test. 
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Figure 4. The effect of serotonin (5-HT) on proliferation in human PASMCs. The 
proliferative response to serotonin in female non-PAH patient control (A), female 
PAH patient (B), male non-PAH patient control (C) and male PAH patient (D) 
human PASMCs (n=3, in triplicate). SB224289 is the selective 5-HT1BR antagonist 
and CP94253 is the selective 5-HT1BR agonist. Data displayed as % of 2.5% FBS 
negative control. *P<0.05, **P<0.01, ****P<0.001, determined by one-way analysis 
of variance with Tukey’s post test. 
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Figure 5. The effect of over-expressing miRNA-96 in human PASMCs from female 
patients. The effect of pre-miRNA-96 transfection in human PASMCs from female 
patients on miRNA-96 expression (A), 5-HT1B mRNA (B) and 5-HT1BR protein (C) 
(n=3, all isolates repeated 3 times). (D) The effect of over-expression of miRNA-96 
on serotonin (5-HT) - induced proliferation in human PASMCs from female PAH 
patients (n=3, all isolates repeated 3 times). Data displayed as mean SEM. 
*P<0.05, **P<0.01, determined by one-way analysis of variance with Tukey’s post 
test. 
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Figure 6. The effect of 17² -estradiol (E2) on miRNA-96 and 5-HT1BR mRNA 
expression. The effect of E2 stimulation on miRNA-96 expression (A) and 5-HT1BR 
mRNA expression (B) in human PASMCs (n=6, all isolates repeated 3 times). The 
effect of depleting endogenous E2  levels by inhibiting aromatase on miRNA-96 
expression (C) and 5-HT1BR mRNA expression (D) in whole female mouse lung 
homogenate (n=5, all isolates repeated 3 times). Data displayed as mean SEM. 
*P<0.05, **P<0.01, determined by one-way analysis of variance with Tukey’s post 
test. 
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Figure 7. The effect of a miRNA-96 mimic on hypoxia-induced pulmonary 
hypertension in female mice. (A) The effect of 30µg dose (i.v.) of miRNA-96 mimic 
on miRNA-96 expression in pulmonary artery (n=5). (B) Representative images of 
miRNA-96 in situ hybridisation in pulmonary arteries from hypoxic mice (Scale bar 
40µ). Effects of miRNA-96 mimic 30µg dose on (C) right ventricular systolic 
pressure (RVSP) (n=9-10), (D) right ventricular hypertrophy (RVH) (n=10) and (E) 
the % of remodelled pulmonary arteries (n=6) in normoxic and hypoxic female mice. 
(F) Representative images of pulmonary arteries (Elastin Van Giesen stain, scale 
bar 50µ). Data displayed as mean SEM. *P<0.05, **P<0.01, ***P<0.001determined 
by unpaired t-test and one-way analysis of variance with Tukey’s post test. 
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Figure 8. The effect of a miRNA-96 mimic on miRNA, mRNA and protein level. (A) 
The effect of hypoxia and miR-96 mimic on BMPR2 expression (n=6), (B) miR-96 
expression (n=6) and (C) 5-HT1BR protein expression (n=6) in whole lung 
homogenate. (D) Schematic outlining proposed pathway: MiRNA-96 normally 
down-regulates the 5-HT1BR which decreases serotonin-induced proliferation of 
pulmonary artery smooth muscle cells (PASMCs). Estrogen, hypoxia and BMPR-II 
deficiency in females can decrease miRNA-96 expression causing an increase in 5-
HT1BR expression which increases serotonin-induced proliferation and this may 
contribute to the pathobiology of PAH in females. Data displayed as mean SEM. 
*P<0.05, ***P<0.001, determined by one-way analysis of variance with Tukey’s post 
test. 
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A sex-specific microRNA-96/5HT1B axis influences development of pulmonary 
hypertension. 
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Methods 
Ethical Information 
All animal procedures conform to the UK Animal Procedures Act (1986) and the 
Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH publication No. 85–23, revised 1996).  Experimental 
procedures using human lung tissue and human PASMCs (hPASMCs) conform to 
the principles outlined in the Declaration of Helsinki and were approved by 
Cambridgeshire 1 Research Ethics committee (REC reference: 08/H0304/56).  All 
non-PAH human lung biopsies were confirmed as macroscopically normal and 
collected from patients undergoing pneumonectomy with no reported presence of 
PAH.  
Pulmonary Artery Smooth Muscle Cell Culture 
Female and male pulmonary artery smooth muscle cells (PASMCs) derived from 
BMPR2+/- R899X mice and littermate wild type control mice were provided by Prof. N. 
W. Morrell (University of Cambridge, Cambridge, UK). BMPR2+/- R899X mice have a 
heterozygous knock-in mutation of the BMPR2 gene. Briefly the main pulmonary 
artery was dissected from 3-6 month old mice and PASMCs were explanted, derived 
and grown in 20% FBS (Foetal Bovine Serum) DMEM Dulbecco’s Modified Eagle 
Medium) with supplement Pack (C-39262, PromoCell, UK) before passage. The 
smooth muscle phenotype was confirmed by positive immunofluorescent staining 
using an antibody to smooth muscle specific ±-actin (Sigma, UK). The cells were 
used between passages 4~6 for experiments. 
Female human PASMCs were provided by Prof. N. W. Morrell (University of 
Cambridge, Cambridge, UK). Briefly human PASMCs were explanted from the small 
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distal pulmonary arteries of the pulmonary vasculature from ten PAH patients, four 
with HPAH, three with IPAH, one with APAH and two with unknown forms of PAH. 
PASMCs derived from non-PAH subjects were utilised as controls. Pulmonary 
hypertension was not suspected on clinical or radiological grounds in these subjects 
and cells were derived from macroscopically normal tissue. HPASMCs were cultured 
in DMEM supplemented with 10% FBS in the presence of antibiotic antimycotic 
solution (containing penicillin, streptomycin and amphotericin). All hPASMCs were 
used between passage 4 and 8 and phenotype was confirmed via smooth muscle 
cell morphology. Details of hPASMCs utilised can be found in Table 1.  
Cell Proliferation Assay 
PASMCs were plated on 24-well or 96-well plates at equal density in 10% FBS 
DMEM. Once the cells reached ~60% confluency they were quiesced in 0.2% FBS 
phenol free DMEM for a period of 24 hours. PASMCs were then brought to 2.5% 
FBS for hPASMCS and 1% for mouse PASMCS and pre-incubated with 300nM of 
the selective 5-HT1B receptor antagonist, SB224289 hydrochloride (Tocris, #1221), 
for 1 hour prior to 72 hour stimulation with either 1µM of serotonin hydrochloride (5-
HT) (Tocris, #3547) or 1µM of the selective 5-HT1B receptor agonist CP94253 
hydrochloride (Tocris, #1317). To asses proliferation PASMCs were counted using 
the haemocytometer approach.  
hPASMCs Transfection with miR-mimic 
PASMCs were plated on 6-well and 24-well plates at equal density in 10% FBS 
DMEM. 50% confluent cells underwent transfection with 1nM pre-miR-96 (Ambion, 
PM10422) or pre-miR-negative control (Ambion, AM17110 #1) using Lipofectamine 
2000 (Invitrogen) and optimem (Invitrogen) for a total of 6 hours before the media 
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was replaced with 10% FBS DMEM. For expression analysis each condition was 
performed in duplicate to allow RNA harvest 48 hours and protein harvest 72 hours 
post-transfection for Taqman and western blot analysis respectively. For proliferation 
analysis PASMCs were then quiesced in 0.2% FBS and the above proliferation 
protocol followed.  
Taqman quantitative-PCR Analysis of miRNAs and mRNAs 
Total RNA was extracted using the miRNeasy kit (Qiagen) according to the 
manufacturer’s instructions and RNA purity quantified using NanoDrop-1000 
Spectrophotometer. Expression of miR and mRNA was assessed by Taqman 
quantitative-PCR as previously described (1, 2). To obtain a fold change miR 
expression data was normalised to U6 (Applied Biosystems, #001973) for mouse 
and RNU48 (Applied Biosystems, #001006) for human. mRNA expression data was 
normalised to GAPDH (Applied Biosystems, #Mm03302249 and #Hs02758991).  
Western Blot Analysis of Protein 
Protein was extracted using the Radio-Immunoprecipitation Assay (RIPA) lysis 
method. The RIPA buffer was supplemented with proteases inhibitors 
phenylmethanesulfonylfluoride (PMSF), soybean trypsin inhibitor and benzamidine. 
Briefly, supplemented RIPA buffer was added to PASMCs which were then agitated 
on ice for 10 minutes. Cell lysates were collected via scraping and left on ice for 30 
minutes to promote disassociation of proteins. Lysates were then briefly sonicated 
before being spun for 10 minutes at 10000rpm 4° to achieve a cell pellet. Protein 
concentration was determined by colorimetric bicinchoninic acid (BCA) assay system 
(Pierce). Protein expression data was normalised to GAPDH and quantified using 
densitometry.  
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Lung Immunohistochemistry 
Mouse lungs inflated with 10% neutral buffered formalin (NBF) were cut into 5 
micron frontal sections for immunohistochemical staining as previously described (3, 
4). Lung sections were stained with elastin and picosirius and remodelling of the 
pulmonary vasculature confirmed by the presence of a double elastic laminae.   
Luicferase Reporter Assay 
The psi-CHECK-2 dual luciferase reporter vector (Promega) was utilised for the 
reporter assay. Briefly, a fragment of the 3’UTR (un-translated region) of the 5-HT1B 
receptor gene was generated by polymerase chain reaction (PCR) from genomic 
mouse DNA and was cloned via the in-fusion cloning method into the multiple 
cloning site of the psi-CHECK-2 vector at the XhoI and the NotI restriction sites. The 
psi-CHECK-2 5-HT1B vector was then sequenced to confirm there was no unwanted 
mutations within the 3’UTR region of the 5-HT1B. Site-directed mutagenesis was 
performed to create a single point substitution mutation in the 5-HT1B 3’UTR to 
further assess miRNA-96 binding. This was confirmed by sequencing analysis. 1ug 
of psi-CHECK-2 control vector, psi-CHECK-2 5HT1B vector or psi-CHECK-2 
mutated 5-HT1B vector along with either pre-miR-96 or pre-miR negative control 
were co-transfected into HeLa cells using Lipofectamine 2000 and optimem for a 
total of 6 hours before being replaced with 10% FBS DMEM. HeLa cells were left for 
48 hours and the luciferase activity measured using the Dual-Glo Luciferase Assay 
System (Promega) and luminescence detection performed via LUMIstar OPTIMA 
microplate reader (BMG Labtech). The renilla luciferase activity was normalised to 
the internal firefly luciferase activity and data expressed as a percentage of the 
internal control.   
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Administration of miRNA-96 mimic 
To assess whether miRNA-96 was involved in the pathology of pulmonary 
hypertension, the miRNA-96 mimic (Applied Biosystems, #MC10422) was 
administered intravenously via the tail vein once a week for 2 weeks using the 
MaxSuppressor™ In Vivo RNA-LANCEr II delivery method as previously described 
to facilitate delivery to the lung (31).  The mimic was prepared in the delivery reagent 
as per manufacturing instructions at a dose of 1.5mg/kg per injection i.e. ~30ug per 
mouse per injection. Negative miRNA mimic (Applied Biosystems) and PBS dosed 
animals were used as controls.  
To confirm that this delivery protocol delivered miRNA-96 to the pulmonary artery, 
miRNA-96 levels were determined in isolated main pulmonary arteries following 
administration of the miRNA-96 mimic. In situ analysis was also performed to 
visualize distribution of miRNA-96 in the lung. 
 
In Vivo Haemodynamics 
Hameodynamic measurements were performed in mice as previously described (3, 
4). Briefly, the left common carotid artery was cannulated to allow continuous 
observation of systemic mean arterial blood pressure (MAP). The right ventricle of 
the heart was catheterised to allow measurement of right ventricular systolic 
pressure (RVSP) via a transdiaphragmatic technique. Data was acquired using 
Biopac (Biopac Systems, CA, USA). After in vivo measurements were obtained mice 
were killed by anaesthetic overdose. Whole hearts were excised and measurement 
of right ventricular hypertrophy (RVH) determined by the ratio of the free right 
ventricle (RV) wall weight and the left ventricle (LV) wall plus septum (S) weight 
(RV/LV+S). Tissues were excised and snap frozen for further analysis. 
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In situ Hybridisation 
In situ hybridization was performed as previously described (5). Briefly 5µm frontal 
plane lung sections were deparaffinised in an ethanol gradient. Sections were then 
treated with proteinase K (20µg/ml) at 37°C for 20 minutes before being fixed with 
4% formaldehyde and ethyl–3– (3–dimethylaminopropyl) carbodiimide (EDC) 
solution. To inactivate endogenous enzymes, lung sections were treated with 
acetylation buffer. Next lung sections were pre-hybridised for 1 hour at probe 
annealing temperature before overnight probe annealing in hybridisation oven. 
Double DIG-labelled (3’ and 5’) miRCURY LNA hsa-miR-96 probe (50nmol/L) and 
miRCURY LNA scramble-miR probe (negative control) were used at hybridisation 
temperature 52°C and 57°C respectively. Post-hybridisation stringency washes with 
saline sodium citrate buffer were performed before inactivation of endogenous 
peroxidise activity by 3% hydrogen peroxide. Immunodetection was carried out by 
the DIG nucleic acid detection kit (ROCHE ~ 11175041910) as per manufacturer’s 
instructions. Positive staining was evident by a purple colour.  
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Table 1. PAH Patient and non-PAH patient information. 
Patient group  Sex  Age  Disease Status  
Non-PAH  Female  58yrs  Mild emphysema  
Female 64yrs  N/A 
Female N/A N/A  
Female 71yrs  Adenocarcinoma  
Female 59yrs  N/A 
Female 70yrs  N/A  
Male 72yrs  N/A 
Male 62yrs  Emphysema 
Male N/A N/A 
Male 68yrs  N/A 
Male 60yrs Squamous cell carcinoma 
Male 75yrs  N/A 
PAH  Female N/A HPAH (N903S)  
Female 33yrs IPAH  
Female 24yrs  IPAH  
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Female N/A PAH  
Female 30yrs  HPAH (R899X)  
Female N/A IPAH 
Male 43yrs  APAH 
Male N/A HPAH (C347R) 
Male 17yrs  HPAH (W9X) 
Male N/A PAH 
  
Table 1. Known characteristics of patients from whom cells were derived. n/a, not 
available; HPAH, heritable pulmonary arterial hypertension (gene mutation in 
parenthesis); IPAH idiopathic pulmonary arterial hypertension; APAH, associated 
pulmonary arterial hypertension. N/A: information not available. 
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 (A) (B) (C)
(D) (E) (F)
(G)  
Figure E1. MiRNA expression in pulmonary artery smooth muscle cells (PASMCs) from 
female and male BMPR2R899X+/- and wild-type (WT) mice. Expression of (A) miRNA-16, 
(B) miRNA-22, (C) miRNA-27b, (D) miRNA-155, (E) miRNA-206, (F) miRNA-145 and 
(G) miRNA-503 in PASMCs from female and male BMPR2R899X+/- and WT mice (n=8, 
all isolates repeated 3 times). Data displayed as mean SEM. *P<0.05, ** P<0.01, 
***P<0.001 determined by one-way analysis of variance with Tukey’s post test. 
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(A) (B)  
Figure E2.  The effect of estrogen on miRNA-96 and 5-HT1B mRNA expression. The 
effect of depleting endogenous 17² -estradiol levels by inhibiting aromatase on 
miRNA-96 expression (A) and 5-HT1B mRNA expression (B) (n=5, all isolates 
repeated 3 times). Data displayed as mean SEM.  
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 (A) (B)  
Figure E3. The effect of a miRNA-96 mimic on hypoxia-induced pulmonary 
hypertension in female mice. The effect of 30µg dose (i.v.) of miRNA-96 mimic on 
(A) mean systemic arterial pressure (mSAP) and (B) heart rate (HR) (n=9-10). Data 
displayed as mean SEM.  
 
 
 
 
 
 
 
13 
 
 
Reference List 
 
 1.  Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, 
MacDonald RA, Greig JA, Robertson KE, Masson R, et al. Dynamic Changes in 
Lung MicroRNA Profiles During the Development of Pulmonary Hypertension 
Due to Chronic Hypoxia and Monocrotaline. Arteriosclerosis Thrombosis and 
Vascular Biology 2010;30:716-U182. 
 2.  Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair 
KM, McClure JD, Southwood M, et al. A Role for MiR-145 in Pulmonary Arterial 
Hypertension / Novelty and Significance. Circ Res 2012;111:290-300. 
 3.  Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 
5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension - Converging 
Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor 
Antagonist GR127935. Circ Res 2001;89:1231-1239. 
 4.  White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, 
Morecroft I, Loughlin L, McClure JD, et al. Activity of the Estrogen-Metabolizing 
14 
 
Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary 
Arterial Hypertension / Clinical Perspective. Circulation 2012;126:1087-1098. 
 5.  Pena JTG, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, Lim 
C, Holoch D, Berninger P, Zavolan M, et al. MiRNA in Situ Hybridization in 
Formaldehyde and EDC-Fixed Tissues. Nat Meth 2009;6:139-141. 
 
 
